These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

212 related articles for article (PubMed ID: 23442043)

  • 41. Macrocyclic compounds as anti-cancer agents: design and synthesis of multi-acting inhibitors against HDAC, FLT3 and JAK2.
    Ning CQ; Lu C; Hu L; Bi YJ; Yao L; He YJ; Liu LF; Liu XY; Yu NF
    Eur J Med Chem; 2015 May; 95():104-15. PubMed ID: 25800646
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Mining for JAK-STAT mutations in cancer.
    Constantinescu SN; Girardot M; Pecquet C
    Trends Biochem Sci; 2008 Mar; 33(3):122-31. PubMed ID: 18291658
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Phosphospecific flow cytometry for pharmacodynamic drug monitoring: analysis of the JAK-STAT signaling pathway.
    Vafadari R; Weimar W; Baan CC
    Clin Chim Acta; 2012 Sep; 413(17-18):1398-405. PubMed ID: 22261016
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Engagement of the B-cell antigen receptor activates STAT through Lyn in a Jak-independent pathway.
    Wang L; Kurosaki T; Corey SJ
    Oncogene; 2007 May; 26(20):2851-9. PubMed ID: 17146444
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Targeting the JAK/STAT Pathway in T Cell Lymphoproliferative Disorders.
    Shouse G; Nikolaenko L
    Curr Hematol Malig Rep; 2019 Dec; 14(6):570-576. PubMed ID: 31741284
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Emerging treatment options for myelofibrosis: focus on pacritinib.
    Chow V; Weissman A; O'Connell CL; Mehrvar A; Akhtari M
    Onco Targets Ther; 2016; 9():2655-65. PubMed ID: 27226728
    [TBL] [Abstract][Full Text] [Related]  

  • 47. TC-PTP and PTP1B: Regulating JAK-STAT signaling, controlling lymphoid malignancies.
    Pike KA; Tremblay ML
    Cytokine; 2016 Jun; 82():52-7. PubMed ID: 26817397
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pacritinib protects dendritic cells more efficiently than ruxolitinib.
    Heine A; Wolf AM; Schlaweck S; Daecke SN; Brossart P; Wolf D
    Exp Hematol; 2021 Aug; 100():37-40. PubMed ID: 34182006
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Profile of pacritinib and its potential in the treatment of hematologic disorders.
    Hatzimichael E; Tsolas E; Briasoulis E
    J Blood Med; 2014; 5():143-52. PubMed ID: 25170285
    [TBL] [Abstract][Full Text] [Related]  

  • 50. GM-CSF activates the Jak/STAT pathway to rescue polymorphonuclear neutrophils from spontaneous apoptosis in young but not elderly individuals.
    Fortin CF; Larbi A; Dupuis G; Lesur O; Fülöp T
    Biogerontology; 2007 Apr; 8(2):173-87. PubMed ID: 17086367
    [TBL] [Abstract][Full Text] [Related]  

  • 51. CYT387, a selective JAK1/JAK2 inhibitor: in vitro assessment of kinase selectivity and preclinical studies using cell lines and primary cells from polycythemia vera patients.
    Pardanani A; Lasho T; Smith G; Burns CJ; Fantino E; Tefferi A
    Leukemia; 2009 Aug; 23(8):1441-5. PubMed ID: 19295546
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Research advances in the role of JAK2 mutations in acute leukemia].
    Zhang HY; Zhai XW
    Zhongguo Dang Dai Er Ke Za Zhi; 2015 Jun; 17(6):644-9. PubMed ID: 26108332
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Discovery of 4-piperazinyl-2-aminopyrimidine derivatives as dual inhibitors of JAK2 and FLT3.
    Li Y; Ye T; Xu L; Dong Y; Luo Y; Wang C; Han Y; Chen K; Qin M; Liu Y; Zhao Y
    Eur J Med Chem; 2019 Nov; 181():111590. PubMed ID: 31408808
    [TBL] [Abstract][Full Text] [Related]  

  • 54. JAK-mutant myeloproliferative neoplasms.
    Levine RL
    Curr Top Microbiol Immunol; 2012; 355():119-33. PubMed ID: 21823028
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Jak/STAT signaling is involved in the inflammatory infiltration of the kidneys in MRL/lpr mice.
    Wang S; Yang N; Zhang L; Huang B; Tan H; Liang Y; Li Y; Yu X
    Lupus; 2010 Sep; 19(10):1171-80. PubMed ID: 20501525
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Dual-target Janus kinase (JAK) inhibitors: Comprehensive review on the JAK-based strategies for treating solid or hematological malignancies and immune-related diseases.
    Shen P; Wang Y; Jia X; Xu P; Qin L; Feng X; Li Z; Qiu Z
    Eur J Med Chem; 2022 Sep; 239():114551. PubMed ID: 35749986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The antagonist of the JAK-1/STAT-1 signaling pathway improves the severity of cerulein-stimulated pancreatic injury via inhibition of NF-κB activity.
    Chen P; Huang L; Zhang Y; Qiao M; Yao W; Yuan Y
    Int J Mol Med; 2011 May; 27(5):731-8. PubMed ID: 21369693
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ubiquitous activation of Ras and Jak/Stat pathways in human HCC.
    Calvisi DF; Ladu S; Gorden A; Farina M; Conner EA; Lee JS; Factor VM; Thorgeirsson SS
    Gastroenterology; 2006 Apr; 130(4):1117-28. PubMed ID: 16618406
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Selective Tyk2 inhibitors as potential therapeutic agents: a patent review (2015-2018).
    He X; Chen X; Zhang H; Xie T; Ye XY
    Expert Opin Ther Pat; 2019 Feb; 29(2):137-149. PubMed ID: 30621465
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Gö6976 is a potent inhibitor of the JAK 2 and FLT3 tyrosine kinases with significant activity in primary acute myeloid leukaemia cells.
    Grandage VL; Everington T; Linch DC; Khwaja A
    Br J Haematol; 2006 Nov; 135(3):303-16. PubMed ID: 16956345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.